v3.26.3
Consolidated Statements of Stockholders' Deficit - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total
Balance (in shares) at Dec. 31, 2024 77,704,188        
Balance at the beginning of the period at Dec. 31, 2024 $ 77 $ 2,574,611 $ (25,886) $ (3,646,873) $ (1,098,071)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 953,414        
Exercise of options $ 1 33,714     33,715
Restricted stock vesting and issuance, net (in shares) 1,201,681        
Restricted stock vesting and issuance, net $ 1       1
Issuance of common stock related to stock purchase agreement (in shares) 72,483        
Issuance of common stock in connection with an employee stock purchase plan   2,827     2,827
Share-based compensation expense   56,029     56,029
Receivable from investor   316     316
Net (loss) income       817,609 817,609
Comprehensive income (loss)     31,816   31,816
Balance (in shares) at Sep. 30, 2025 79,931,766        
Balance at the end of the period at Sep. 30, 2025 $ 79 2,667,497 5,930 (2,829,264) (155,758)
Balance (in shares) at Jun. 30, 2025 79,378,145        
Balance at the beginning of the period at Jun. 30, 2025 $ 78 2,631,180 7,356 (2,845,160) (206,546)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 486,129        
Exercise of options $ 1 16,829     16,830
Restricted stock vesting and issuance, net (in shares) 67,492        
Share-based compensation expense   19,426     19,426
Receivable from investor   62     62
Net (loss) income       15,896 15,896
Comprehensive income (loss)     (1,426)   (1,426)
Balance (in shares) at Sep. 30, 2025 79,931,766        
Balance at the end of the period at Sep. 30, 2025 $ 79 2,667,497 5,930 (2,829,264) (155,758)
Balance (in shares) at Dec. 31, 2025 81,474,366        
Balance at the beginning of the period at Dec. 31, 2025 $ 80 2,748,335 10,501 (2,964,229) (205,313)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 648,218        
Exercise of options $ 1 24,985     24,986
Restricted stock vesting and issuance, net (in shares) 1,361,190        
Restricted stock vesting and issuance, net $ 1       1
Repurchase of 2026 Convertible Notes   (102,734)     (102,734)
Conversion of 2026 Convertible Notes (in shares) 3,506        
Conversion of 2026 Convertible Notes   (2,899)     (2,899)
Issuance of common stock related to stock purchase agreement (in shares) 48,487        
Issuance of common stock in connection with an employee stock purchase plan   3,163     3,163
Share-based compensation expense   70,539     70,539
Receivable from investor   2     2
Net (loss) income       28,994 28,994
Comprehensive income (loss)     (7,948)   (7,948)
Balance (in shares) at Sep. 30, 2026 83,535,767        
Balance at the end of the period at Sep. 30, 2026 $ 82 2,741,391 2,553 (2,935,235) (191,209)
Balance (in shares) at Jun. 30, 2026 83,327,286        
Balance at the beginning of the period at Jun. 30, 2026 $ 82 2,712,080 6,017 (2,883,542) (165,363)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 141,755        
Exercise of options   5,349     5,349
Restricted stock vesting and issuance, net (in shares) 66,726        
Share-based compensation expense   23,827     23,827
Receivable from investor   135     135
Net (loss) income       (51,693) (51,693)
Comprehensive income (loss)     (3,464)   (3,464)
Balance (in shares) at Sep. 30, 2026 83,535,767        
Balance at the end of the period at Sep. 30, 2026 $ 82 $ 2,741,391 $ 2,553 $ (2,935,235) $ (191,209)